Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Https://x.com/carlsmythecells/status/1783622630370672689?s=46&t=HzmcQkvT8EXSpQM7UblACw
Https://x.com/conceptionmaria/status/1785047936147083715?s=46&t=HzmcQkvT8EXSpQM7UblACw
There is increasing interest in the the development of diagnostics for people with blood-borne bacterial infections. If left untreated, patients will develop sepsis - an acute and life-limiting physiological response which arises from inflammatory signals generated by the immune system. These signals emerge as neutrophils - specialised white blood cells - try to contain the infection, which they do by committing suicide and in so doing extruding their DNA and cellular content to generate a physical net or trap that catches and kills infecting bacteria.
For clinicians, people with blood with blood-borne infections present two challenges:-
(i) what is the nature of the infection (bacteraemia) and how to bring it under control, and
(ii) whether an infection will precipitate sepsis, requiring acute treatment to ensure the patient can avoid septic shock and survive long enough to allow for (i) to happen.
When clinicians suspect bacteraemia, the major challenge is concerned with diagnosis and identification of the infectious species, which determines the nature of antibiotic treatment required. At present, this takes up to 48h and involves lengthy culture of blood samples to enable specific identification of the bacteria present.
The recent reports of tests for sepsis (https://www.independent.co.uk/news/health/sepsis-blood-test-fast-nhs-b2465476.html)are specfically designed to detect the traps set by dying neutrophils, enabling clinicians to treat the life-threatening aspects of sepsis which include a sudden drop in blood pressure, blood-clotting, blood vessel damage and tissue/organ failure. These tests are complementary to the approach adopted by Paraytec Ltd , and allow clinicians to address (ii) but do nothing to address (i).
The Paraytec test is designed to address the issue outlined in (i), using molecular diagnostics and highly sensitive optical imaging to detect the presence of bacteria in samples obtained from blood without prior culture, and to distinguish Gram + from Gram - bacteria. Knowing the Gram status of organisms allows clinicians to make key decisions about antibiotic selection, as well as to suggest the source of infection enabling additional interventional measures.
We've had a rise to 1.20 before and at that time it was mostly substantial news.
Now we're are in a position were BRH can licence or sell CE marked products. At the end of the day nothing is promised but I definitely see the potential to achieve over the pound mark but, as always it down to the board who need to deliver for the VERY PATIENT and FRUSTATED shareholders.